Literature DB >> 22177366

Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome.

Babak Pourakbari1, Setareh Mamishi, Leila Kohan, Leila Sedighi, Shima Mahmoudi, Fatemeh Fattahi, Mostafa Teymuri.   

Abstract

Lethal toxic encephalopathy due to shigellosis or Ekiri syndrome is a rare complication of shigellosis with a high fatality rate. Data are very limited on factors that can predict this encephalopathy, so we evaluated clinical and laboratory characteristics for these patients. In this study children with extreme toxicity and convulsions followed by rapid neurological deterioration resulting in brain edema and fatal outcome without sepsis and severe dehydration were selected as having lethal toxic encephalopathy. There were 1295 children with shigellosis during the 10 years of the study. Five children (0.4%) had lethal toxic encephalopathy due to shigellosis. Death occurred following rapid neurological detoriation resulting in brain edema despite intensive treatment. Evidence of brain edema may be a prediction factor for death. Early recognition of encephalopathy and measures to prevent brain edema may improve patient outcome.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 22177366     DOI: 10.1016/j.jmii.2011.09.005

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  3 in total

1.  An adult case with shigellosis-associated encephalopathy.

Authors:  Heleen Joséphine Schuster; Michelle Gompelman; Wim Ang; Albertus Jozef Kooter
Journal:  BMJ Case Rep       Date:  2018-01-18

2.  Risk factors and outcome of Shigella encephalopathy in Bangladeshi children.

Authors:  Farzana Afroze; Tahmeed Ahmed; Monira Sarmin; Abu Smsb Shahid; K M Shahunja; Lubaba Shahrin; Mohammod Jobayer Chisti
Journal:  PLoS Negl Trop Dis       Date:  2017-04-28

Review 3.  Acute diarrhea with blood: diagnosis and drug treatment.

Authors:  Mara Alves da Cruz Gouveia; Manuela Torres Camara Lins; Giselia Alves Pontes da Silva
Journal:  J Pediatr (Rio J)       Date:  2019-10-08       Impact factor: 2.990

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.